Newsroom / Industry / Industry / Preclinical Models

Preclinical Models

New Approaches for Conducting Preclinical Studies Improve the Quality of Preclinical Data and Speed up the Preclinical R&D Process
London, London, United Kingdom ( 25/02/2011
Pharmaceutical/biotechnology companies partner with CROs, academic and government institutions to design and develop new approaches and models for conducting preclinical research. Advancements in molecular biology/genetic engineering and computational methods help researchers to tackle various problems in the preclinical research.

Simulation and system biology models improve the quality and reliability of preclinical data. Novel models by several pharmaceutical companies and contract research organizations proved to be effective in reducing preclinical process cycle time.

For Sample Pages, please click or add the below link to your browser:

Preclinical studies make use of systems or models such as in-vitro, in-vivo and in-silico models, for conducting a wide range of preclinical research and development studies. Absorption, distribution, metabolism, excretion and toxicology (ADMET) studies are conducted initially to investigate and correlate the test compound’s absorption, distribution, metabolism, excretion, and toxicology profile in preclinical systems with humans. There is considerable number of contract research organizations (CROs), providing a wide range of preclinical design and testing services. Some of the top CROs such as Charles River Laboratories, Covance and Cyprotex offer both customized and standardized preclinical services and models to their clients (pharmaceutical and biotechnology companies) and they continue to grow with strategic acquisitions and partnerships. Furthermore CROs from Asian countries (especially from India and China) such as Jubilant Biosys, Advinus and Shanghai ChemPartner also emerging up with their customized preclinical offerings.

GBI Research, the leading business intelligence provider, has released its latest report, “Preclinical Models- Preclinical CROs will Continue to Improve the Quality and Accuracy of Data for Targeted Therapies” that provides key data, information and analysis of the major trends and developments in preclinical studies and preclinical outsourcing business. The report provides a comprehensive insight into key technological developments, new approaches in developing preclinical models. The report talks about the key outsourcing business models and factors that are driving the global preclinical outsourcing market. The report also provides a detailed analysis of global preclinical market in terms of preclinical spending and preclinical outsourced value. The report also provides key alliances and acquisitions related to preclinical studies among CROs.

This report is built using data and information sourced from proprietary databases, primary and secondary research and in house analysis by GBI Research’s team of industry experts.

For further details, please click or add the below link to your browser:

Visit our report store:

For more details contact:
North America: +1 646 395 5477
Europe: +44 207 753 4299
+44 1204 543 533
Asia Pacific: +91 40 6616 6782


GBI Research is a global market intelligence services company providing information research and analysis products and services.


Rajesh Gunnam

John Carpenter House, John Carpenter Street
Zipcode : EC4Y 0AN

Category :
Industry:Industry Subscribe to Industry Keywords :
Preclinical Models, CROs, Pharmaceuticals, Healthcare